Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 20191046 | HLA-DQB1*05 | melas | Korean | NA | NA | unclassified | |
| mitochodrial dna studies for melas and merrf were negative in those children and hla-drb1*1401, hla-drb3*0202, and hla-dqb1*0502 seemed to be significant. | |||||||
| 20191046 | HLA-DRB3*02 | merrf | Korean | NA | NA | unclassified | |
| mitochodrial dna studies for melas and merrf were negative in those children and hla-drb1*1401, hla-drb3*0202, and hla-dqb1*0502 seemed to be significant. | |||||||
| 20191046 | HLA-DRB3*02 | melas | Korean | NA | NA | unclassified | |
| mitochodrial dna studies for melas and merrf were negative in those children and hla-drb1*1401, hla-drb3*0202, and hla-dqb1*0502 seemed to be significant. | |||||||
| 8704196 | HLA IDENTICAL (HLA-IDENTICAL) | myelodysplastic syndromes | French | cyclophosphamide | NA | unclassified | |
| we report on 71 consecutive patients with de novo myelodysplastic syndromes referred to physicians belonging to the societe francaise de greffe de moelle from 1982 through 1991 and transplanted with marrow from hla-identical siblings. | |||||||
| 12901342 | HLA MATCHED (HLA-MATCHED) | busulfan | NA | cyclophosphamide | NA | unclassified | |
| NA | |||||||
| 23475532 | HLA-DR (HLA-DR) | myelodysplastic syndromes | NA | NA | NA | unclassified | |
| combined flow cytometric assessment of cd45, hla-dr, cd34, and cd117 expression is a useful approach for reliable quantification of blast cells in myelodysplastic syndromes. | |||||||
| 28865971 | HLA (HLA) | myelodysplastic syndromes | NA | NA | NA | unclassified | |
| this study aimed to validate the capability of the center for international blood and marrow transplant research (cibmtr) prognostic scoring system to predict outcomes of patients with myelodysplastic syndromes (mds) who had undergone hla-haploidentical related donor hematopoietic stem cell transplantation (haplo-hsct). | |||||||
| 28865971 | HLA (HLA) | hematopoietic stem cell transplantation | NA | NA | NA | unclassified | |
| this study aimed to validate the capability of the center for international blood and marrow transplant research (cibmtr) prognostic scoring system to predict outcomes of patients with myelodysplastic syndromes (mds) who had undergone hla-haploidentical related donor hematopoietic stem cell transplantation (haplo-hsct). | |||||||
| 32420357 | HLA-B4 (BROAD ANTIGEN) | myelodysplastic syndromes | NA | NA | NA | unclassified | |
| kir3dl1 and hla-bw4 interaction showed a favorable role in patients with myelodysplastic syndromes in chinese southern han. | |||||||
| 32957333 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | myelodysplastic syndromes | NA | methylprednisolone | NA | unclassified | |
| patient concerns: a 31-year-old male who was diagnosed as "myelodysplastic syndromes with excess blasts ii" (intermediate risk 2 of international prognostic scoring system) received human leukocyte antigen -matched sibling donor allogeneic hematopoietic stem cell transplantation. | |||||||
Copyright 2024